Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Regulation Medicare Reimbursement

Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers

  • Analysis

Executive Summary

Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside  Medicare's reimbursement bundle for end-stage renal disease.

Table

View full table

Advertisement

Related Content

Pink Sheet
US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best
Scrip
Phase III Roxadustat ALPS Data Positive For New Class Of Anemia Therapies
Pink Sheet
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
Scrip
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

Topics

Related Companies

Advertisement
Tags:
Regulation Medicare Reimbursement
UsernamePublicRestriction

Register

PS123955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By